Guardant Health GH Biopharma and data — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Guardant Health in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Guardant Health’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Guardant Health's biopharma and data — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Guardant Health's biopharma and data — total revenue?
- Guardant Health (GH) reported biopharma and data — total revenue of $52.98M in Q1 2026.
- How has Guardant Health's biopharma and data — total revenue changed year-over-year?
- Guardant Health's biopharma and data — total revenue increased by 16.8% year-over-year, from $45.38M to $52.98M.
- What is the long-term trend for Guardant Health's biopharma and data — total revenue?
- Over 2 years (2023 to 2025), Guardant Health's biopharma and data — total revenue has grown at a 24.1% compound annual growth rate (CAGR), from $136.35M to $210.13M.
- What does biopharma and data — total revenue mean?
- This metric represents the total gross revenue generated from partnerships, clinical trial support, and data licensing services provided to biopharmaceutical companies. It reflects the company's ability to monetize its proprietary genomic databases and diagnostic platforms through collaborative research and development engagements. This revenue stream is distinct from clinical testing services and highlights the company's role as a strategic partner in drug development and precision oncology research.